Hutchmed scores U.S. success with cancer drug, but profits still dip
The drug developer has reported sharply reduced profits, coming off an exceptionally high base last year, but sales of its key cancer medicine are accelerating in the United States Key…
Recent Articles
RELATED ARTICLES
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG -
CSPC Pharma weighs up diet drug for bigger bottom line
1093.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene’s aggressive expansion brings revenue jolt
BGNE.US 6160.HK 688235.SHG
-
RemeGen hopes for pain relief from expanded drug uses
9995.HK 688331.SHG
-
AstraZeneca pays hefty price for Chinese weight-loss drug
AZN.US
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
